Symbols

ICU

SeaStar Medical·NASDAQ

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 1

Stock Price Surged Significantly

MACD Golden Cross

Gap Up

Low Cash Short-term Debt Ratio

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ICU

Seastar Medical Holding Corp

A medical technology company developing innovative solutions for critically ill patients, including extracorporeal therapies

Industry

Healthcare Equipment and Supplies

Established Date

06/06/2007

Listing Date

03/18/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.seastarmedical.com

Security Type

Common stock

Office address

3513 Brighton Blvd, Suite 410, Denver, CO 80216

Business

Introduction

SeaStar Medical Holding Corp was originally incorporated in Delaware on June 6, 2007 under the name Nephrion, Inc. On August 3, 2007, the company changed its name to CytoPherx Corporation. On June 19, 2019, in a merger transaction, CytoPherx was renamed SeaStar Medical, a commercialization stage healthcare company focused on developing treatments for critically ill patients facing organ failure. Its core technology, the Selective Cell Adsorption Device, is designed to modulate over-activated immune cells and respond to excessive inflammation. The Company has received regulatory approval for its pediatric therapies and is advancing clinical trials for adult indications. With a number of regulatory approvals that help speed up the R&D process, the agency has established a unique industry position as the only company with approved products for specific pediatric patient groups.

Company Financials

EPS

ICU has released its 2025 Q4 earnings. EPS was reported at -0.8, versus the expected -1.08, beating expectations. The chart below visualizes how ICU has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

ICU has released its 2025 Q4 earnings report, with revenue of 420.00K, reflecting a YoY change of 526.87%, and net profit of -2.90M, showing a YoY change of 34.28%. The Sankey diagram below clearly presents ICU's revenue sources and cost distribution.